GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback